The accomplishments attained by Ms. Tara M. Raghavan in the field of Legal Services, warrants inclusion into the Top Attorneys of North America.
“I attribute my success to working with the right people.” – Tara M. Raghavan
Rakoczy Molino Mazzochi Siwik LLP is a full-service litigation and intellectual property law firm. Since the firm’s inception in 2004, RMMS has handled litigation matters in the pharmaceutical industry, including specialty practice in the field of patent and regulatory counseling and litigation under the Hatch-Waxman Act, the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), and the Biologics Price Competition and Innovation Act (BPCIA). With over 30 attorneys at the firm, their experience is unparalleled in the industry. They devoted their entire practice to pharmaceutical and biologics work, RMMS has become intimately familiar not only with their clients’ legal issues, but also the business, legislative, regulatory, and political hurdles facing their clients.
Tara M. Raghavan is a partner at Rakoczy Molino Mazzochi Siwik LLP. She is license to practice in the State of Illinois, the Federal Circuit Court of appeals N.D. Illinois and is registered to practice before the United States Patent and Trademark Office and has had significant experience preparing and prosecuting patents. Her practice focuses on complex patent litigation, including pre-suit strategy development, fact and expert discovery, the pre-trial and trial phases of federal litigation, as well as experience at the federal appellate level, counseling, and opinion work, particularly relating to the Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act.
Ms. Raghavan was a key member of the team that secured a victory at the District Court and Federal Circuit levels, not only defeating a preliminary injunction motion but also invalidating two patents upon summary judgment relating to the drug Boniva® (ibandronate). She was also a member of the trial team that secured an invalidity ruling with respect to a patent related to the drug Pulmicort Respules® (budesonide); Ms. Raghavan was further an integral member of the team that secured a Federal Circuit en banc ruling affirming summary judgment of non-infringement involving the drug Omnicef® (cefdinir). She is also a member of the team that defeated a motion for temporary restraining order and preliminary injunction involving the drug Altace® (ramipril). Ms. Raghavan has further participated in patent litigation involving such drugs as Tricor® (fenofibrate), Namenda® (memantine), Trilipix® (fenofibrate), and Sprycel® (dasatinib); each of these cases was resolved by settlement on favorable terms for RMMS clients.
Prior to attending the University of Illinois College of Law (J.D., 2003), Ms. Raghavan received her B.S. in Chemistry, from the University of Illinois and worked as an organic chemistry intern for Stat Analysis (Hi Tek Environmental), an environmental testing firm in Chicago’s Technology Park, where she prepared soil samples for chlorine and CFC analysis. Obtaining her B.A. Economics, she served as a Research Assistant for the University of Illinois at Chicago Economics Department. In that capacity, Ms. Raghavan helped to organize Emissions Trading conferences at the Federal Reserve Bank in Chicago and edit conference volumes.
Ms. Raghavan is a member of the Indian American Bar Association of Chicago, Advisory Council, the South Asian Bar Association of North America, and the Chicago Tyagaraja Utsavam (Indian Classical Music Organization), Board Member. She is also a published author and is recognized as Top Women Attorney in Intellectual Property-Chicago Magazine, 2015 and Super Lawyers Rising Star 2014-Present.
The Top Attorneys of North America, a New York based publication, distinguishes and profiles leading attorneys who have reached a recognizable degree of success and leadership in their field. The directory is valued for promoting awareness of the accomplishments within the North American legal community.